IMD business school for management and leadership courses

While GSK’s 2025 growth strategy is anchored in specialty medicines and five planned product launches, the company underscores AI’s role in bolstering R&D and commercial efficiency. In December 2024, GSK committed $45m to London-based Relation to identify novel targets for fibrotic diseases and osteoarthritis. GSK’s in-house algorithms already support applications such as predicting lupus responses, uncovering latent hepatitis B infections, and guiding treatment strategies – reducing research cycles and improving development efficiency. 

The company employs “lab-in-the-loop” learning cycles, where active feedback loops refine experiments around high-value targets. External datasets from UK Biobank, the Alliance for Genomic Discovery, and NIH’s All of Us enrich internal research, increasing global relevance and probability of approval. GSK.ai – its London-based innovation hub – leads AI-driven initiatives in drug development, computational pathology, and genomics, supported by strategic partnerships with firms like Cerebras and Relation. 

GSK also emphasizes ethical deployment of AI. A dedicated AI Governance Council, Responsible AI team, and internal policy framework uphold principles of fairness, transparency, and patient safety.